Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by ZyVersa Therapeutics < Previous 1 2 Next > ZyVersa Therapeutics Announces Published Data Demonstrating That Plasma Levels of Inflammasome ASC Show Promise as Biomarker of Early Cognitive Changes in Older Adults July 29, 2024 From ZyVersa Therapeutics Via GlobeNewswire Tickers ZVSA ZyVersa Therapeutics Selects Obesity and Related Metabolic Complications as Lead Indication for Inflammasome ASC Inhibitor IC 100 July 25, 2024 From ZyVersa Therapeutics Via GlobeNewswire Tickers ZVSA ZyVersa Therapeutics Announces Publication Demonstrating that Inflammasome ASC Inhibitor IC 100 Restored Retinal Structure and Function in a Retinopathy of Prematurity Animal Model July 18, 2024 From ZyVersa Therapeutics Via GlobeNewswire Tickers ZVSA ZyVersa Therapeutics' CEO, Stephen C. Glover, Is an Invited Speaker at H.C. Wainwright 3rd Annual Kidney Conference to be Held Virtually on July 15, 2024 July 09, 2024 From ZyVersa Therapeutics Via GlobeNewswire Tickers ZVSA ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update May 15, 2024 From ZyVersa Therapeutics Via GlobeNewswire Tickers ZVSA ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International Convention May 14, 2024 From ZyVersa Therapeutics Via GlobeNewswire Tickers ZVSA ZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer’s Disease April 29, 2024 From ZyVersa Therapeutics Via GlobeNewswire Tickers ZVSA ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes April 04, 2024 From ZyVersa Therapeutics Via GlobeNewswire Tickers ZVSA ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update March 25, 2024 From ZyVersa Therapeutics Via GlobeNewswire Tickers ZVSA ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator™ VAR 200 in Patients with Diabetic Kidney Disease March 18, 2024 From ZyVersa Therapeutics Via GlobeNewswire Tickers ZVSA ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled “Inflammation Illuminated,”at Benzinga’s Virtual Healthcare Summit 2024 on March 20, 2024 March 14, 2024 From ZyVersa Therapeutics Via GlobeNewswire Tickers ZVSA ZyVersa Therapeutics Generated Approximately $2.7 Million From Exercise of Warrants Following Excitement Around News That Inflammasome Inhibitors Have Potential to Effectively Treat Obesity February 29, 2024 From ZyVersa Therapeutics Via GlobeNewswire Tickers ZVSA ZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100’s Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its Complications February 28, 2024 From ZyVersa Therapeutics Via GlobeNewswire Tickers ZVSA ZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic Option February 22, 2024 From ZyVersa Therapeutics Via GlobeNewswire Tickers ZVSA ZyVersa Therapeutics Highlights Review Article Substantiating That Inflammasome Activation Is Pathogenic in Multiple Neurological Diseases February 14, 2024 From ZyVersa Therapeutics Via GlobeNewswire Tickers ZVSA ZyVersa Therapeutics' CEO, Stephen C. Glover to Present at the 2024 BIO CEO & Investor Conference to Provide Corporate Update and Discuss Key Milestones February 07, 2024 From ZyVersa Therapeutics Via GlobeNewswire Tickers ZVSA ZyVersa Therapeutics Highlights Publication Indicating That Inflammasome NLRP3-Mediated Inflammation in Obese Children Leads to Insulin Resistance and Risk of Complications Such as Type 2 Diabetes January 31, 2024 From ZyVersa Therapeutics Via GlobeNewswire Tickers ZVSA ZyVersa Therapeutics Announces Peer-Reviewed Article Supporting the Therapeutic Potential of Targeting ASC Specks During Progression of Alzheimer’s Disease January 24, 2024 From ZyVersa Therapeutics Via GlobeNewswire Tickers ZVSA ZyVersa Therapeutics Highlights Peer-Reviewed Article Linking Inflammasome Activation to Triple-Negative Breast Cancer Brain Metastasis January 17, 2024 From ZyVersa Therapeutics Via GlobeNewswire Tickers ZVSA ZyVersa Therapeutics’ CEO, Stephen C. Glover, Featured on Benzinga All Access January 10, 2024 From ZyVersa Therapeutics Via GlobeNewswire Tickers ZVSA ZyVersa Therapeutics Announces Equity Research Coverage Initiated by Noble Capital Markets January 04, 2024 From ZyVersa Therapeutics Via GlobeNewswire Tickers ZVSA ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Providing Outlook for 2024 January 03, 2024 From ZyVersa Therapeutics Via GlobeNewswire Tickers ZVSA ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Participate in BIO Partnering @ JPM During “J.P. Morgan Week 2024” December 18, 2023 From ZyVersa Therapeutics Via GlobeNewswire Tickers ZVSA ZyVersa Therapeutics Engages CRO, George Clinical, for Phase 2a Clinical Trial for Cholesterol Efflux Mediator VAR 200 December 14, 2023 From ZyVersa Therapeutics Via GlobeNewswire Tickers ZVSA ZyVersa Therapeutics Announces Publication Demonstrating That Plasma Levels of NLRP3 Inflammasomes Correlate with Progression of Diabetic Kidney Disease in Patients with Type 2 Diabetes December 07, 2023 From ZyVersa Therapeutics Via GlobeNewswire Tickers ZVSA ZyVersa Therapeutics, Inc. Announces Pricing of $5.0 Million Public Offering December 06, 2023 From ZyVersa Therapeutics Via GlobeNewswire Tickers ZVSA ZyVersa Therapeutics Announces Publication Showing AIM2 and NLRP3 Inflammasomes Promote Atherosclerosis in Diabetes, Supporting IC 100’s Rationale for Targeting ASC to Inhibit Multiple Inflammasome Pathways December 06, 2023 From ZyVersa Therapeutics Via GlobeNewswire Tickers ZVSA ZyVersa Therapeutics, Inc. Announces Reverse Stock Split and Increase in Authorized Shares of Common Stock November 30, 2023 From ZyVersa Therapeutics Via GlobeNewswire Tickers ZVSA ZyVersa Therapeutics Reports Third Quarter 2023 Corporate Update and Financial Results November 14, 2023 From ZyVersa Therapeutics Via GlobeNewswire Tickers ZVSA ZyVersa Therapeutics Announces Article Published in Peer-Reviewed Biomedical Journal Demonstrating That NLRP3 Inflammasome Inhibition Attenuates Inflammatory Bowel Disease Symptoms in Animal Model November 09, 2023 From ZyVersa Therapeutics Via GlobeNewswire Tickers ZVSA < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.